Shackelford Pharma congratulates O’Neill D’Cruz, a member of Shackelford’s clinical development team, and our Scientific Advisory Board Members Emilio Perucca and Jeffrey Buchhalter, co-authors of the article “EEG Parameters as
real world experience
Shackelford Pharma is built on Dr. Shackelford's real world experience and insights. This represents over 25,000 real patient interactions with real outcomes. Shackelford's team has analyzed patient outcomes to identify the most promising therapeutic candidates for development. Shackelford Pharma has exclusive access to these insights.
Our therapeutic focus
Shackelford is focused on epilepsy. Our drug candidate (SP1707) is supported by 133 patient treatment years of data from patients under the care of Dr. Shackelford. Our mission is to bring this new medicine through the development and FDA regulatory process to benefit people with epilepsy with unmet medical needs.
43 FDA Drug Approvals
Our world-class R&D team has over 320 years of collective pharmaceutical drug development experience. All have enjoyed key leadership roles in the development of 43 drugs that have been approved by the FDA. This includes 7 which have sold over $1B per year and 6 anti-epileptic drugs.
Shackelford Pharma Inc. Selected to Present at Life Science BC Invest in BC Vancouver BC, Canada (October 16, 2022) — Shackelford Pharma Inc., a pharmaceutical company developing medicines for neurological
Vancouver BC, Canada (October 16,2022) — Shackelford Pharma Inc. (“Shackelford” or the “Company”), a pharmaceutical company developing medicines for neurological diseases with significant unmet patient needs, is pleased to announce